CeGaT has expanded its sequencing capacities by integrating a second NovaSeq™ X Plus system into its laboratory. This new addition complements the existing five NovaSeq™ 6000 sequencers and the initial NovaSeq™ X Plus acquired last year.
The NovaSeq™ X Plus will be utilized for a wide range of genomic applications: The Research & Pharma Solutions business unit offers a comprehensive portfolio of sequencing services for customers in academia, the pharmaceutical sector, and industry.
CeGaT’s guiding principle of always relying on the latest technologies is reflected in its continuous investments: Last year, CeGaT was one of the first companies in the world to receive the NovaSeq™ X Plus shortly after its market launch. It was also the first company in Germany to acquire PacBio’s Sequel IIe system, which is equipped with Single Molecule Real-Time (SMRT) technology. The recent acquisition of a second NovaSeq™ X Plus underlines CeGaT’s leading role in the field of sequencing.